Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study

NCT04934475 is registered in ClinicalTrials.gov with Intergroupe Francophone du Myelome as lead sponsor.

NCT NCT04934475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04934475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study
Lead sponsor
Intergroupe Francophone du Myelome
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 8, 2021
Completion date
September 30, 2028
Enrollment
791 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma